AA
CRNX

AlphaCentric Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

AlphaCentric Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Buy
+9,866
New +$367K 0.31% 111
2023
Q4 		– Sell
-82,000
Closed -$2.44M – 241
2023
Q3 		$2.44M Buy
82,000
+35,000
+74% +$721K 1.38% 19
2023
Q2 		$847K Buy
+47,000
New +$937K 0.47% 73

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaCentric Advisors's CRNX Position: Q2 2026 in Review

AlphaCentric Advisors opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 9,866 shares worth $369K. The stake represents 0.31% of the portfolio and ranks #111 among its holdings. This is a return to the name: AlphaCentric Advisors previously reported a position in CRNX as recently as Q3 2023.

AlphaCentric Advisors first reported a position in CRNX in Q2 2023 and has held it in 3 quarters since. The position peaked at $2.44M in Q3 2023. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • AlphaCentric Advisors held 9,866 shares of Crinetics Pharmaceuticals worth $369K as of Q2 2026.
  • Crinetics Pharmaceuticals was a new AlphaCentric Advisors position in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.31% of AlphaCentric Advisors's portfolio in Q2 2026, its #111 holding.
  • AlphaCentric Advisors first reported a position in Crinetics Pharmaceuticals in Q2 2023 and has held it in 3 quarters since.
  • AlphaCentric Advisors's Crinetics Pharmaceuticals position peaked at $2.44M in Q3 2023.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.